GERN Earnings

GERN reported its FY2025Q4 earnings on 2026-03-09, showcasing a revenue of against an estimate of 56.92M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.03 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following GERN's FY2025Q4 earnings announcement on 2026-03-09, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, GERN's stock price tends to shift by an average of 8.95% in the 10 days leading up to earnings and -1.9% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate GERN's annual revenue to reach 53.85M, while the EPS is projected at -0.03. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GERN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GERN's stock price typically moves by 8.95% in the 10 days before its earnings and -1.9% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.03 and revenue of 53.85M.

The earnings call summary indicates strong financial performance with significant revenue growth and reduced R&D expenses. The Q&A section highlights a refined strategy and optimistic guidance for future growth, despite some vague responses. The company is targeting high-volume accounts and has a path to profitability, although not immediate. The strategic plan and market expansion efforts, including European approval, suggest positive momentum. However, some risks remain, such as supply chain scalability and clinical trial outcomes. Given the small-cap nature of the company, the overall sentiment is positive, with potential for a stock price increase of 2% to 8%.